Avastin plus chemotherapy prolonged PFS in patients with previously treated GBM

Avastin plus chemotherapy demonstrated a 2.7-month increase (4.2 months vs 1.5 months) in median PFS compared with chemotherapy alone (HR=0.52 [95% CI, 0.41–0.64]).[1]

No difference in OS (HR=0.91, P=0.4578) was observed between arms; therefore, all secondary outcome measures are descriptive only

GBM=glioblastoma; PFS=progression-free survival; HR=hazard ratio; CI=confidence interval.

*Insurer/payer policies are subject to change. The completion and submission of coverage or reimbursement-related documentation are the responsibility of the patient and the healthcare provider. Genentech makes no guarantee concerning coverage or reimbursement for any service or item. Inclusion of a plan or product is not intended to imply a recommendation of a particular plan or product. Coverage percentage shown is a weighted average based on national patients treated for Avastin.
As of 01/01/2021, national coverage for Avastin is 85%+.